Microangiopathic hemolytic anemia

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Microangiopathic hemolytic anemia
Classification and external resources
Specialty hematology
ICD-10 D59.4
ICD-9-CM 283.19
DiseasesDB 29721

In medicine (hematology), microangiopathic hemolytic anemia (MAHA) is a microangiopathic subgroup of hemolytic anemia (loss of red blood cells through destruction) caused by factors in the small blood vessels. It is identified by the finding of anemia and schistocytes on microscopy of the blood film.


In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and malignant hypertension, the endothelial layer of small vessels is damaged with resulting fibrin deposition and platelet aggregation. As red blood cells travel through these damaged vessels, they are fragmented resulting in intravascular hemolysis. The resulting schistocytes (red cell fragments) are also increasingly targeted for destruction by the reticuloendothelial system in the spleen, due to their narrow passage through obstructed vessel lumina. It is seen in systemic lupus erythematosus, where immune complexes aggregate with platelets, forming intravascular thrombi. Microangiopathic hemolytic anemia is also seen in cancer.[1]

Automated analysers (the machines that perform routine full blood counts in most hospitals) are generally programmed to flag blood films that display red blood cell fragments or schistocytes.[citation needed]


In all causes, the mechanism of MAHA is the formation of a fibrin mesh due to increased activation of the system of coagulation. The red blood cells are physically cut by these protein networks. The resulting fragments are the schistocytes observed in light microscopy.


Microangiopathic hemolytic anemia results in isolated increase in serum bilirubin levels. Unconjugated hyperbilirubinemia above 15% is present. The differential diagnoses are rifampicin or probenecid use, inherited disorders like Gilbert's syndrome and other hemolytic disorders.[2]



CP reduced plasma: Because platelets and cryoprecipitate are contraindicated as they facilitate further clot formation and RBC lysis.


  1. ^ Lechner K, Obermeier HL (July 2012). "Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases". Medicine. 91 (4): 195–205. doi:10.1097/MD.0b013e3182603598. PMID 22732949. 
  2. ^ "Harrison's Principles of Internal Medicine, 19th Edition Textbook". www.harrisonsim.com. Retrieved 14 January 2018. 
  3. ^ "UpToDate". www.uptodate.com.